RSCM
BBIO icon

Rock Springs Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Rock Springs Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.52M Buy
128,250
+24,750
+24% +$1.79M 0.56% 50
2025
Q4 		$7.92M Buy
103,500
+18,500
+22% +$1.21M 0.41% 57
2025
Q3 		$4.41M Buy
+85,000
New +$4.15M 0.26% 67

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rock Springs Capital Management's BBIO Position: Q1 2026 in Review

Rock Springs Capital Management increased its BridgeBio Pharma (BBIO) stake by 24% in Q1 2026, buying an estimated $1.79M and bringing the position to 128,250 shares worth $9.52M. The position accounts for 0.56% of the portfolio, ranked #50.

Rock Springs Capital Management first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Rock Springs Capital Management held 128,250 shares of BridgeBio Pharma worth $9.52M as of Q1 2026.
  • Rock Springs Capital Management bought 24,750 BridgeBio Pharma shares in Q1 2026, an estimated $1.79M.
  • BridgeBio Pharma made up 0.56% of Rock Springs Capital Management's portfolio in Q1 2026, its #50 holding.
  • Rock Springs Capital Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.